EUVIMEDEUVIMED entdecken
Crossref

Beyond the Rash: How Omalizumab Shapes Mental Health Outcomes in Chronic Spontaneous Urticaria

Tugba Kiratli Yolcu, Volkan Bozkurt, Sedat Demirsoy, Dilan Sirin, Cengiz Kirmaz

International Archives of Allergy and Immunology · 2025

DOI: 10.1159/000548659 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2025. Verfasst von Tugba Kiratli Yolcu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Clinical Immunology, Celal Bayar University Faculty of Medicine, Manisa, Turkey, drtugbakiratli@gmail.com. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents, Urticaria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chronic spontaneous urticaria (CSU) is defined as urticaria lasting at least 6 weeks. Its symptoms (itching, redness, wheals, etc.) significantly impair quality of life and psychological well-being. This study aimed to assess the effect of omalizumab on anxiety, depression, and stress in CSU patients.

Method

This study prospectively evaluated patients diagnosed with CSU who were treated with six doses of omalizumab. A series of assessments were conducted prior to and following the administration of treatment. These included the Perceived Stress Scale (PSS), the Hospital Anxiety and Depression Scale (HADS: HADS-Anxiety [HADS-A] and HADS-Depression [HADS-D]), the Weekly Urticaria Activity Score (UAS7), and the Urticaria Control Test (UCT). The results for HADS-A and HADS-D were further classified as normal, borderline, or abnormal.

Results

A total of 34 patients (8 males, 26 females) with a mean age of 38.5 ± 9.9 years were included in the study. Following treatment, 31 of 34 patients (91%) achieved notable reduction in the UAS7 score, aligning with the minimal clinically important difference (9.5–10.5) criteria. A significant decrease was observed in HADS and PSS scores, while a significant increase was noted in UCT scores (p < 0.001 for all parameters). A significant decrease in the UAS7 score was observed in all subcategories of the HADS-A and HADS-D assessments at the 6-month evaluation period. However, no significant change was observed between subcategories.

Conclusion

The omalizumab treatment has positive impact on urticaria activity, psychological parameters, and stress condition in CSU patients. The presence of anxiety and depression at baseline does not impact the efficacy of the treatment. Nevertheless, patients exhibiting elevated psychological stress or anxiety/depression scores in the absence of urticaria control should be referred for further psychiatric evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabChronic UrticariaAnti-Allergic AgentsUrticariaHumansFemaleAdultMaleMiddle AgedTreatment OutcomeQuality of LifeAnxietyDepressionMental HealthStress, Psychological

Stichwörter der Autor:innen

AnxietyChronic spontaneous urticariaDepressionOmalizumabStress

Substanzen

OmalizumabAnti-Allergic Agents

Autor:innen und Institutionen

  • Department of Allergy and Clinical Immunology, Celal Bayar University Faculty of Medicine, Manisa, Turkey, drtugbakiratli@gmail.com.
  • Department of Allergy and Clinical Immunology, Celal Bayar University Faculty of Medicine, Manisa, Turkey.

Zitieren

APA

Kiratli Yolcu, T., Bozkurt, V., Demirsoy, S., Sirin, D., & Kirmaz, C. (2025). Beyond the Rash: How Omalizumab Shapes Mental Health Outcomes in Chronic Spontaneous Urticaria. International Archives of Allergy and Immunology. https://doi.org/10.1159/000548659

Vancouver

Kiratli Yolcu T, Bozkurt V, Demirsoy S, Sirin D, Kirmaz C. Beyond the Rash: How Omalizumab Shapes Mental Health Outcomes in Chronic Spontaneous Urticaria. International Archives of Allergy and Immunology. 2025. doi:10.1159/000548659

BibTeX
@article{KiratliYolcu2025,
  author = {Kiratli Yolcu, Tugba and Bozkurt, Volkan and Demirsoy, Sedat and Sirin, Dilan and Kirmaz, Cengiz},
  title = {Beyond the Rash: How Omalizumab Shapes Mental Health Outcomes in Chronic Spontaneous Urticaria},
  journal = {International Archives of Allergy and Immunology},
  year = {2025},
  doi = {10.1159/000548659}
}
Kostenlos starten →